Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has presented updates on its innovative cancer treatments at the 2024 European Society of Medical Oncology (ESMO) Congress. The company highlighted the Phase I study results for irpagratinib, a novel small-molecule FGFR4 inhibitor, in patients with FGF19 over-expressing advanced hepatocellular carcinoma (aHCC). The study indicated an overall response rate (ORR) of 44.8%, with a median duration of response (mDoR) of 7.4 months and a median progression-free survival (mPFS) of 5.5 months.
Additionally, Abbisko reported on the Phase I/II study of pimicotinib, a small-molecule inhibitor of CSF-1R, in combination with chemotherapy and toripalimab for first-line advanced pancreatic ductal adenocarcinoma. While specific data from this study remains undisclosed, the presentation at ESMO has sparked interest in the potential synergistic effects of these treatments. – Flcube.com
